Covington & Burling said this week that it is launching a Boston office this spring with “broad-based life sciences capabilities,” another sign of Am Law 100 law firms—and their clients—flocking to the city for its biotech opportunities.

“We have seen more and more of our Big Pharma clients relocating operations to Boston,” said Covington chair Doug Gibson. “That combined with just the level of expertise out of the great universities in Boston has also created sort of, more of a biotech and emerging company hub for life sciences. So when you combine those two factors, it’s just, it’s a more and more important market for life sciences.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]